Edition:
United States

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

20.09USD
24 Mar 2017
Change (% chg)

$-0.21 (-1.03%)
Prev Close
$20.30
Open
$20.50
Day's High
$20.50
Day's Low
$19.81
Volume
81,246
Avg. Vol
104,125
52-wk High
$22.90
52-wk Low
$9.24

Latest Key Developments (Source: Significant Developments)

Newlink Genetics Q4 loss per share $0.46
Tuesday, 28 Feb 2017 08:00am EST 

Newlink Genetics Corp :Qtrly total revenue $12.7 million versus. $7.7 million, qtrly loss per share $0.46.  Full Article

Newlink Genetics Corp says it entered into a controlled equity offering(SM)sales agreement with Cantor Fitzgerald & Co
Tuesday, 29 Nov 2016 04:57pm EST 

Newlink Genetics Corp : Newlink Genetics Corp says on Nov 29, 2016 co entered into a controlled equity offering(SM)sales agreement with Cantor Fitzgerald & Co-SEC filing . Newlink Genetics - May offer and sell, through Cantor, shares of co's stock par value $0.01 per share, aggregate offering price of up to $40.0 million .Will pay Cantor a commission rate of up to 3.0% of aggregate gross proceeds from each sale of shares.  Full Article

Newlink Genetics Q2 loss per share $1.12
Friday, 29 Jul 2016 08:00am EDT 

Newlink Genetics Corp : Q2 loss per share $1.12 . Implemented a significant restructuring program following may results of impress phase 3 study of algenpantucel-l . Reducing headcount from approximately 230 to approximately 130 . Recorded $12.3 million in restructuring expenses in q2 . Winding down hyperacute cellular immunotherapy clinical trials that do not include a checkpoint inhibitor combination .In q3, company expects to record small additional charges relating to closing or reduction of leased facilities.  Full Article

Newlink Genetics elected to terminate Wuxi agreement
Monday, 6 Jun 2016 05:27pm EDT 

Newlink Genetics Corp: Elected to terminate Wuxi agreement . Determined to discontinue manufacturing operations for Algenpantucel-L and to terminate Wuxi agreement .Expects to make certain payments under outstanding work orders in connection with termination.  Full Article

Newlink Genetics announces results from phase 3 impress trial of Algenpantucel-L
Monday, 9 May 2016 04:01pm EDT 

Newlink Genetics : Impress phase 3 study of Algenpantucel-l for patients with resected pancreatic cancer did not achieve its primary endpoint . L for patients with resected pancreatic cancer did not achieve its primary endpoint . Overall survival from time of randomization was 29.3 months for both groups combined . There was also no statistical difference for long-term survival. . Newlink genetics corp says there was no statistically significant difference between two groups . "in light of these negative results, our scientific and clinical teams will focus on other promising opportunities in our pipeline" . Newlink genetics corp says reiterates that its goal and expectation is to finish 2016 with two years of cash on hand .L for patients with resected pancreatic cancer.  Full Article

NewLink Genetics Corp presents Phase 1b Data of Indoximod in Combination With Gemcitabine/Nab-Paclitaxel for Patients With Metastatic Pancreatic Cancer
Friday, 22 Jan 2016 08:00am EST 

NewLink Genetics Corp:Announces the presentation of data that describe a combination therapy of indoximod, an IDO pathway inhibitor, plus gemcitabine/nab-paclitaxel, for patients with metastatic pancreatic cancer.Combination immunotherapeutic approach was well tolerated and shows encouraging durable responses with a delayed pattern.  Full Article

NewLink Genetics Corp awarded $18 million contract option from barda
Thursday, 1 Oct 2015 07:00am EDT 

NewLink Genetics Corp:Awarded $18 million contract option from barda.  Full Article

NewLink Genetics Corp receives $8.1 Million contract from DTRA
Thursday, 24 Sep 2015 04:00pm EDT 

NewLink Genetics Corp:Says Defense Threat Reduction Agency of United States Department of Defense has awarded subsidiary of NewLink Genetics an $8.1 mln base contract.Says this includes with future options totaling $5.2 mln to support various development activities of the investigational rVSV-ZEBOV (Ebola) vaccine candidate.NewLink has exclusively licensed research, development and manufacturing of the rVSV-ZEBOV vaccine to Merck.  Full Article

NewLink Genetics Corp says vaccine candidate potentially effective against ebola in large trial in Guinea
Friday, 31 Jul 2015 08:19am EDT 

NewLink Genetics Corp:Says the international partnership studying the vsv-zebov (ebola) vaccine candidate in guinea has released interim data.Says data suggesting that it is effective against ebola in a large clinical trial.Results suggest that vaccine candidate demonstrates efficacy within about 10 days of administration to a person without the infection.Says Merck is now responsible for research, development and manufacturing of the rvsv-zebov vaccine.  Full Article

More From Around the Web

BRIEF-Newlink Genetics Q4 loss per share $0.46

* Qtrly total revenue $12.7 million versus. $7.7 million, qtrly loss per share $0.46 Source text for Eikon: Further company coverage: